DIAPH3 Antibody

What is DIAPH3 and what cellular functions does it regulate?

DIAPH3 (Diaphanous-related formin-3, also known as DIAP3, MDia2, or DRF3) is an actin nucleation and elongation factor required for the assembly of F-actin structures, including actin cables and stress fibers. It functions in multiple cellular processes:

• Cytokinesis

• Stress fiber formation

• Transcriptional activation of serum response factor

• GTP-bound Rho binding and profilin recruitment

• Membrane-localized actin polymerization

• Nuclear actin polymerization driving SRF-MRTFA activity

The protein has an approximate mass of 137 kDa and plays a crucial role in regulating actin dynamics, which impacts cell morphology, migration, and division .

How does altered DIAPH3 expression affect different cellular phenotypes?

DIAPH3 expression changes drive distinct cellular phenotypes in a context-dependent manner:

These contradictory findings highlight the tissue-specific and context-dependent functions of DIAPH3 in different cancer types .

What criteria should researchers consider when selecting DIAPH3 antibodies?

When selecting a DIAPH3 antibody, consider:

• Target epitope location - Different antibodies target different regions of DIAPH3:

  • C-terminal region (aa 1100 to C-terminus)

  • Middle region (aa 700-1150)

  • Full-length protein

• Host species and antibody type:

  • Rabbit polyclonal antibodies (suitable for IP, WB, IHC-P)

  • Mouse polyclonal antibodies (suitable for WB)

• Validated applications:

  • Western blotting (WB)

  • Immunoprecipitation (IP)

  • Immunohistochemistry (IHC-P)

• Citation record and published validation data

Select antibodies with demonstrated specificity in applications matching your experimental needs and validated in publications relevant to your research context .

What validation methods ensure DIAPH3 antibody specificity?

To validate DIAPH3 antibody specificity:

• Knockdown validation: Compare antibody signal between control and DIAPH3-silenced cells (using siRNA or shRNA). Specific antibodies will show decreased signal intensity in knockdown samples.

• Molecular weight verification: Confirm the detected band appears at the predicted molecular weight (137 kDa for full-length DIAPH3).

• Positive controls: Use cell lines known to express DIAPH3 (HeLa cells show robust DIAPH3 expression suitable as positive controls) .

• Negative controls: Include:

  • Control IgG in immunoprecipitation experiments

  • Secondary antibody-only controls

  • Non-expressing tissue samples

• Immunoprecipitation validation: Verify antibody can specifically pull down DIAPH3 from cell lysates, with band detection by Western blot .

How can DIAPH3 antibodies be optimized for Western blotting?

For optimal Western blotting with DIAPH3 antibodies:

• Sample preparation:

  • Prepare cell lysates in RIPA buffer containing protease inhibitors (HALT protease inhibitor mixture)

  • Load 50-100 μg protein per lane

• Gel electrophoresis conditions:

  • Use 4-20% gradient Tris-HCl gels for optimal separation

  • Transfer to PVDF membranes

• Blocking and antibody incubation:

  • Block with 5% nonfat dry milk in TBS-T (Tris-buffered saline/0.1% Tween-20, pH 8)

  • Primary antibody dilutions:

    • 1:2,000 for DT154 anti-DIAPH3

    • 1:1,000 for commercial DIAPH3 antibodies

  • Secondary antibody: HRP-conjugated anti-rabbit/mouse IgG (1:10,000)

• Detection system:

  • For high sensitivity: Supersignal West Femto Maximum Sensitivity Substrate

  • For standard detection: Pierce ECL Western Blotting Substrate

  • Exposure time: Approximately 10 seconds is often sufficient

• Normalization control:

  • Use GAPDH (sc-25778, 1:1,000 dilution) as loading control

  • Calculate DIAPH3/GAPDH ratio for quantification

Expected result: Detection of a 137 kDa band corresponding to full-length DIAPH3 .

What protocols are effective for DIAPH3 immunoprecipitation studies?

For effective DIAPH3 immunoprecipitation:

• Cell lysate preparation:

  • Prepare lysate from 1 mg cell protein using NETN lysis buffer

  • Include protease and phosphatase inhibitors

• Antibody binding:

  • Use 6 μg anti-DIAPH3 antibody per reaction

  • Pre-clear lysate with Protein A/G beads

  • Incubate lysate with antibody overnight at 4°C

• Controls:

  • Include control IgG immunoprecipitation

  • Load 20% of IP for Western blot analysis

• Detection:

  • Use 1 μg/ml anti-DIAPH3 for Western blot detection of immunoprecipitated protein

  • Use chemiluminescence detection with 3-second exposure

• Protein interaction studies:

  • For co-immunoprecipitation studies investigating DIAPH3 interactions (e.g., with FOXM1), include additional antibodies against potential interaction partners

This protocol has been validated for HeLa cells and can be adapted for other cell lines expressing DIAPH3 .

How does DIAPH3 function in cancer progression and immune infiltration?

DIAPH3 exhibits complex roles in cancer:

• Prognostic biomarker:

  • High DIAPH3 expression correlates with better prognosis in colorectal cancer

  • Serves as a diagnostic and prognostic marker in cervical cancer

  • Elevated in multiple cancer types compared to normal tissues

• Immune cell infiltration relationships:

  • DIAPH3 expression in cervical cancer negatively correlates with:

    • B cell infiltration

    • Macrophage infiltration

    • Dendritic cell infiltration

    • Effector T cell infiltration

  • Positively correlates with:

    • Lymphoid progenitor cells

    • Th2 CD4+ T cells

• Immune checkpoint correlations:

  • Negatively correlates with immune checkpoints in testicular carcinoma and cervical cancer:

    • CTLA4

    • HAVCR2

    • LAG3

    • PDCD1

    • TIGIT

  • Positively correlates with most immune checkpoints in hepatocellular carcinoma and lung adenocarcinoma

These findings suggest that DIAPH3 expression may influence tumor immunotherapy response, with tissue-specific effects on immune cell recruitment and checkpoint expression .

What molecular mechanisms underlie DIAPH3's role in different pathologies?

DIAPH3 operates through several key molecular mechanisms:

• In colorectal cancer:

  • DIAPH3 maintains EGFR degradation

  • Acts as a protective factor associated with better prognosis

  • Inhibits CRC progression

• In hearing loss (AUNA1):

  • c.-172G > A mutation in 5' UTR upregulates DIAPH3 expression (2-3 fold increase)

  • Increases both mRNA and protein levels (1.48-fold in heterozygotes, 1.62-fold in homozygotes)

  • Disrupts organization of actin filaments affecting hearing function

• In anaplastic thyroid carcinoma:

  • DIAPH3 interacts with FOXM1

  • Modulates Wnt/β-catenin signaling

  • DIAPH3 deletion:

    • Represses cell proliferation, migration, and invasion

    • Enhances apoptotic capabilities

    • Decreases BCL2 expression

    • Increases Bax and cleaved caspase3 expression

• In hepatocellular carcinoma:

  • DIAPH3 binds HSP90 to activate β-catenin/TCF signaling

These diverse mechanisms highlight DIAPH3's context-dependent functions across different pathologies and cellular systems .

What strategies effectively silence DIAPH3 expression in experimental models?

For effective DIAPH3 silencing:

• siRNA approach:

  • Design multiple siRNA constructs targeting different regions

  • Test knockdown efficiency of each construct

  • Example: In ATC studies, siRNA-DIAPH3-1 showed more potent reduction than siRNA-DIAPH3-2

  • Confirm knockdown by Western blot and RT-qPCR

• shRNA approach:

  • In colorectal cancer studies, sh-1 construct (named sh-DIAPH3) showed greatest knockdown effect compared to empty vector (sh-NC)

  • Validate at both protein and mRNA levels

• Validation parameters:

  • Western blotting using validated anti-DIAPH3 antibodies

  • RT-qPCR with appropriate primers

  • Functional assays to confirm phenotypic effects

• Control selection:

  • Include empty vector controls (sh-NC)

  • Non-targeting siRNA controls

Successful silencing should demonstrate >70% reduction in DIAPH3 expression at both mRNA and protein levels before proceeding with functional studies .

How can researchers reconcile contradictory findings about DIAPH3 function across different cancer types?

To reconcile contradictory DIAPH3 findings:

• Consider tissue-specific contexts:

  • DIAPH3 silencing promotes proliferation in colorectal cancer

  • But inhibits proliferation in cervical cancer, pancreatic cancer, and osteosarcoma

• Methodological approach:

  • Employ multiple cell lines from the same cancer type

  • Use both in vitro and in vivo models

  • Apply consistent experimental conditions and readouts

  • Validate findings with patient samples

• Molecular pathway analysis:

  • Investigate tissue-specific interaction partners (e.g., FOXM1 in ATC, HSP90 in hepatocellular carcinoma)

  • Examine downstream signaling pathways (Wnt/β-catenin, EGFR)

  • Analyze expression of actin-regulating cofactors that may modulate DIAPH3 function

• Experimental design considerations:

  • Include rescue experiments to confirm specificity

  • Perform time-course studies to capture dynamic changes

  • Use multiple silencing approaches (transient vs. stable)

• Data interpretation framework:

  • Report comprehensive methodological details

  • Acknowledge limitations and context-specificity

  • Consider genetic background differences between cell lines

  • Examine extracellular matrix and microenvironment effects

This comprehensive approach helps establish that DIAPH3 functions are highly context-dependent and influenced by tissue-specific molecular networks .

What emerging techniques may enhance DIAPH3 research beyond traditional antibody applications?

Emerging techniques for advanced DIAPH3 research:

• CRISPR-Cas9 gene editing:

  • Generate DIAPH3 knockout cell lines

  • Create point mutations mimicking disease-associated variants

  • Introduce fluorescent tags at endogenous loci

• Live-cell imaging of DIAPH3 dynamics:

  • CRISPR knock-in of fluorescent tags

  • Super-resolution microscopy to visualize actin-DIAPH3 interactions

  • FRAP (Fluorescence Recovery After Photobleaching) to measure dynamics

• Proximity labeling approaches:

  • BioID or APEX2 fusions to identify proximal interactors

  • Temporal mapping of dynamic interaction networks

• Single-cell analysis:

  • scRNA-seq to identify cell populations with differential DIAPH3 expression

  • Spatial transcriptomics to map DIAPH3 expression in tumor microenvironments

• Structural biology approaches:

  • Cryo-EM to resolve DIAPH3 protein complexes

  • Hydrogen-deuterium exchange mass spectrometry to map interaction surfaces

• Patient-derived organoids:

  • Test DIAPH3 function in more physiologically relevant models

  • Evaluate cancer-type specific functions

These approaches will complement antibody-based detection methods and provide deeper insights into DIAPH3's context-dependent functions .

How might targeting DIAPH3 inform potential therapeutic approaches?

DIAPH3-targeted therapeutic considerations:

• Cancer type-specific approaches:

  • Inhibition strategies for cancers where DIAPH3 promotes progression (ATC, cervical cancer)

  • Enhancement strategies for cancers where DIAPH3 suppresses progression (colorectal cancer)

• Combination with immunotherapy:

  • DIAPH3 correlates with immune checkpoint expression in multiple cancers

  • TMB (Tumor Mutation Burden) analysis shows significant correlation with DIAPH3 expression levels

  • May predict immunotherapy response

• Targeting protein-protein interactions:

  • Disrupting DIAPH3-FOXM1 interaction in ATC

  • Modulating DIAPH3-HSP90 binding in hepatocellular carcinoma

  • Affecting DIAPH3's role in EGFR degradation

• Actin cytoskeleton modulation:

  • Small molecules targeting DIAPH3's actin nucleation activity

  • Pathway-specific approaches affecting downstream signaling

• Translational considerations:

  • DIAPH3 as a biomarker for treatment selection

  • Expression levels may predict prognosis in a cancer-type specific manner

These approaches require rigorous validation in preclinical models before clinical translation, with careful consideration of the context-dependent functions of DIAPH3 across different cancer types .